Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)

Supportive Care in Cancer

Volumn 20, Issue 10, 2012, Pages 2633-2637

  Hesketh, Paul J ^a   Morrow, Gary ^b   Komorowski, Anna W ^c   Ahmed, Raza ^d   Cox, David ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Hematology Oncology Associates of Rockland County   (United States)

^d EISAI INC   (United States)

Author keywords

Efficacy; Low emetogenic chemotherapy; Nausea and vomiting; Palonosetron; Safety; Serotonin antagonists

Indexed keywords

DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IXABEPILONE; PACLITAXEL; PALONOSETRON; PEMETREXED; TOPOTECAN;

ADULT; ARTICLE; CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DECREASED APPETITE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LOW EMETOGENIC CHEMOTHERAPY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PATIENT SAFETY; PILOT PROJECTS; QUINUCLIDINES; SALVAGE THERAPY; TREATMENT OUTCOME; VOMITING;

EID: 84868497141     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1527-3     Document Type: Article

References (15)

1. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268 (Pubitemid 38580348)
2. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. Antiemesis, version 3.2011. http://www.nccn.org/ professionals/ physician-gls/pdf/antiemesis. pdf. Accessed 21 February 2011
3. Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB et al (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12(Suppl 4):32-37
4. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503 (Pubitemid 46570778)
5. Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori E, Borjeson S (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13:109-111 (Pubitemid 40558166)
6. Schwartzberg L, Szabo S, Gilmore J, Haislip S, Jackson J, Jain G et al (2011) Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/ HEC). Curr Med Res Opin 27:837-845
7. Craver C, Gayle J, Balu S, Buchner D (2011) Delayed and overall chemotherapy-induced nausea and vomiting (CINV) in cancer patients on single-day low emetogenic chemotherapy (LEC) [abstract]. Presented at the 2011 International Symposium of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), Athens, Greece, June 23-25, 2011
8. Yang LP, Scott LJ (2009) Palonosetron: in the prevention of nausea and vomiting. Drugs 69:2257-2278
9. Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44:520-531 (Pubitemid 38509721)
10. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193-199
11. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577 (Pubitemid 37304615)
12. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482 (Pubitemid 37466663)
13. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441- 1449 (Pubitemid 44400384)
14. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124
15. Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - state of the art. Support Care Cancer 19(Suppl 1):S43-S47